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                                     INTRODUCTION 
 
Two decade after acquired immunodeficiency syndrome (AIDS) was 
recognized as a distinct, new entity in 1981, over 60 million individuals worldwide 
have been infected by the causative human immunodeficiency virus, HIV-1. 
 
The Discovery of HIV was a milestone in the history of AIDS. Later on 
elaborate research and studies were conducted and the impacts of HIV on human 
immune system were revealed. 
 
One of the vastly studied materials is the destruction of CD4+ T Lymphocytes 
by HIV, a key factor in the pathogenesis of the disease. 53, 25 
 
The CD 4 helper cells play a major role in the body’s immune system. The 
CD4 cells are undoubtedly much reduced in number with advanced disease and this 
correlation of CD 4 cells and AIDS progression have been studied elaborately by 
researchers. 
   
Nowadays the disease progression and emergence of opportunistic infections 
are predicted by CD 4+ T helper cell counts. The CD 4 cells help to recognize the 
foreign agents and with the help of other T cell lineages tend to contain the infection 
and eliminate the infective agents. 
 8
 
 
 
By destroying the CD4 cells the HIV gain access to the body without any 
resistance if at all and cause a varied syndrome. Many of the studies have shown an 
inverse relationship with CD4 cells and viral load. 
 
The CD4 counts are the predictors of disease progression and to plan the 
necessary treatment even though there are other parameters available. 
 
The antiretroviral drugs by eliminating the virions tend to increase the CD4+ 
cells indirectly and this has been proved to a large extent. The invention of HAART 
has promising effects in modulating the CD4 counts and decreasing the incidence of 
opportunistic infections especially tuberculosis in our country. 
 
 The present study aims at evaluating the treatment outcome to the highly 
active retroviral therapy (HAART) among the study population in terms of 
immunological response, clinical response and functional status improvement. 
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AIMS OF THE STUDY 
 
 
1. To evaluate the immunological response of HIV infected adults starting Highly 
Active Antiretroviral Therapy (HAART). 
 
2. To evaluate the clinical response of Highly Active Antiretroviral Therapy in 
HIV infected adults. 
 
3. To assess the functional status improvement following Highly Active    
          Antiretroviral Therapy. 
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HISTORICAL REVIEW 
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MILESTONES IN THE HISTORY OF HIV AND AIDS17 
 
Pre-1970’s HIV transmitted to humans in Africa, probably from  
chimpanzee source.  
1970’s Unrecognized global spread of HIV 
1981  Epidemic pneumocystis pneumonia and Kaposi’s 
   Sarcoma reported in New York, Los Angeles and San  
Francisco. 
1983  New human retrovirus isolated from a patient in France 
1984  Retrovirus confirmed as cause of AIDS, CD4 shown to  
be its binding receptor. 
   Screening for HIV antibodies in doubted blood  
introduced in industrialized countries. 
1986  HTLV- LAV renamed Human Immunodeficiency Virus  
(HIV) by the International committee for Taxonomy of virus. 
Effective prevention of pneumocystis pneumonia by  
co-trimoxazole and other drugs. 
   HIV-2 isolated from West African patients 
1987  Zidovudine improves survival in AIDS. 
1990  Antigenic variation warns that development of HIV   
vaccines will not be easy. 
1993  Concorde trial demonstrates that survival benefits from  
Zidovudine immunotherapy is not sustained. 
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1994  Zidovudine shown to reduce vertical transmission of HIV  
by two thirds. 
 
HHV-8 discovered as the cause of Kaposi’s sarcoma.                          
 
1995  High HIV and immune cell turnover demonstrated during   
asymptomatic phase of HIV infection. 
   Dual combinations of nucleosides shown to be superior  
to monotherapy.  
 
1996 Prognostic value of plasma HIV RNA estimation (Viral load) 
demonstrated. 
Protease inhibitors in triple regimens show marked reduction in 
progression to AIDS and death over the short to medium term. 
Chemokine co-receptors for HIV demonstrated mutant receptors 
confer resistance to HIV infection in some exposed uninfected 
subjects. 
 
1997  Non- nucleoside reverse transcriptase inhibitors  
introduced. 
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1998  Epidemiological studies show major reduction in death  
rates in  patients with AIDS on triple therapy. 
Vertical transmission of HIV shown to be reduced by  
elective cesarean section. 
 
2001  Inexpensive antiretroviral treatment available in resource  
poor countries . 
 
2004           Government of India initiated supply of free                                
                              ART to HIV infected patients. 
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REVIEW OF LITERATURE 
 
INTRODUCTION 
 
 
The acquired immunodeficiency syndrome (AIDS) was first recognized in 
1981.   It is caused by the human immunodeficiency virus (HIV-1). HIV-2 causes a 
similar illness to HIV-1 but is less aggressive and restricted mainly to western Africa. 
 
Immune deficiency is a consequence of continuous high-level HIV replication 
leading to virus and immune –mediated destruction of the key immune effector cell, 
the CD4 lymphocyte. 
 
EPIDEMIOLOGY 5 
 WORLD  
Recognized as an emerging disease only in the early 1980’s, AIDS has rapidly 
established itself throughout the world and is likely to persist in the 21st century. 
GLOBAL HIV- AIDS EPIDEMIC AS ON DECEMBER 2006. 
NUMBER OF PEOPLE LIVING WITH HIV IN 2006.54 
Total 39.5 million 
Adults 37.2 million 
Women 17.7 million 
Children under 15 years  2.3 million 
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PEOPLE NEWLY INFECTED WITH HIV IN 2006 
Total 4.3 million 
Adults 3.8 million 
Children under 15 years 530,000 
 
AIDS DEATHS IN 2006 
Total 2.9 million 
Adults 2.6 million 
 
 INDIA  
Now in its third decade, India’s epidemic is marked by heterogeneity-not a 
single epidemic but made up of a number of distinct epidemics, in some places within 
the same state. 
 
Based on sentinel surveillance data, the HIV prevalence in adult population can 
be broadly classified into three groups of States / UTs in the country. 
 
  High Risk 
group 
Antenatal 
women 
Group - I High prevalence states  
eg. Tamilnadu 
> 5 % > 1 % 
Group –II Moderate prevalence states  
eg. Gujarat, Goa 
> 5 % < 1 % 
Group-III Low Prevalence Status < 5 % < 1 % 
   
The cumulative number of AIDS cases in the country has risen to 124995 by 
August 2006. 
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  THE ROUTE OF INFECTION IN INDIA, AUG. 2006 39 
 
Risk/ Transmission categories Percentage 
Sexual 85.34 
Perinatal Transmission 3.80 
Blood and Blood products 2.05 
Injecting drug users 2.34 
Others (not specified) 6.46 
 
AIDS is affecting mainly the young people in sexually active age group. 
Majority of the HIV infections (88.55%) are in the age group of 15- 49 years, out of 
which 31.8 % are in the age group of 15 - 29 years.5, 39 
 
Males account for 60.59 percent of AIDS cases and females 29.40 percent. The 
ratio being 2.4: 1. 
 
The most predominant opportunistic infections among AIDS patients is 
tuberculosis followed by candidiasis.38 
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ETIOLOGIC AGENT14  
 
HIV is a single stranded RNA retrovirus from the lentivirus family.  There are 
two types, HIV-1 and HIV-2. The most common cause of HIV disease throughout the 
world is HIV-1.  HIV-2 is almost entirely confined to West Africa. 
Retroviruses are characterized by the possession of the enzyme reverse 
transcriptase, which allow viral RNA to be transcribed into DNA, and thence 
incorporated into the host cell genome. 
Reverse transcriptase is an error-prone process with a significant rate of 
misincorporation of bases.  
           This combined with high rate of viral turnover, leads to considerable genetic 
variation and a diversity of viral subtypes or clades. 
 
VIRAL GENOME 14 
 
The HIV genome is a single stranded RNA, 9200 bases long. Presence of long 
terminal repeats (LTR’s) at either end of the genome is a property of retroviruses. 
HIV-1 has genes that encode the structural proteins of the virus. gag encodes 
proteins that form the core of the virion; pol encodes the enzymes responsible for 
reverse transcription and integration; env encodes the envelope glycoprotein. 
It also contains atleast six other genes (tat, rev, nef, vif, vpr, and vpu) which   
code for proteins involved in the regulation of gene expression. 
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VIRUS REPLICATION 14 
 
STAGE STEPS IN REPLICATION DRUG TARGETS 
1 Attachment to CD4 receptor  
2 
Binding to co-receptor CCR5 or 
CXCR4 
CCR5/CXCR4 receptor 
inhibitors 
3 Fusion Fusion inhibitors 
4 Reverse Transcription  
Nucleoside and non- nucleoside 
reverse transcriptase inhibitors 
5 Integration Integrase inhibitors 
6 Transcription  
7 Translation  
8 
Cleavage of polypeptides and 
assembly 
Protease  inhibitors 
9 Viral release  
 
                                      MODES OF TRANSMISSION 
 
HIV is present in blood, semen, and other body fluids such as breast milk and 
saliva. 
The modes of spread are sexual (man to man, Heterosexual and oral), 
parenteral (blood or blood product recipients, injection drug users and those 
experiencing occupational injury) and vertical.   
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CLINICAL MANIFESTATIONS 
 
The clinical consequences of HIV infection encompass a spectrum ranging 
from an acute syndrome associated with primary infection to a prolonged 
asymptomatic state to advanced disease. 
 
1. THE ACUTE HIV SYNDROME 15, 45  
 
It is experienced that 50-70% of individuals with HIV infection experience an 
acute clinical syndrome approximately 3 to 6 wks after primary infection.  Most 
patients recover spontaneously from this syndrome. 
 
 CLINICAL FINDINGS IN THE ACUTE HIV SYNDROME. 
 
NEUROLOGIC 
Meningitis 
Encephalitis 
Peripheral neuropathy 
Myelopathy 
GENERAL 
Fever 
Pharyngitis 
Lympadenopathy 
Headache/ Retro orbital pain 
Arthralgia / Myalgia 
Anorexia / Weight loss 
Nausea / vomiting / diarrhea 
DERMATOLOGIC 
Erythematous maculopapular rash 
Mucocutaneous ulceration 
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2. THE ASYMPTOMATIC STAGE - CLINICAL LATENCY 48  
 
The length of time from initial infection to the development of clinical disease 
various greatly, the median time for untreated patients is 10 years. 
 During this period the patient is clinically asymptomatic and generally has no 
findings on physical examination except in some cases for persistent generalized 
lymphadenopathy (PGL). 
The rate of disease progression is directly correlated with HIV RNA level. 
During the asymptomatic period of HIV infection, the average rate of  
CD4 + T cell decline is 50/mm3 per year. 
 
 
3.   SYMPTOMATIC HIV INFECTION (CD4 COUNT 200-499 CELLS /MM3,    
CATEGORY B SYMPTOMS, CDC CLINICAL CLASSIFICATION).46, 48 
 
During the symptomatic HIV infection, the skin and mucous membranes are 
predominantly involved. 
These diseases corresponded to AIDS-related complex (ARC) conditions but 
by definition are not AIDS- defining. 
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4.   AIDS (CD4 COUNT 50-200 CELLS/ MM3, CATEGORY- C SYMPTOMS, 
CDC CLINICAL   CLASSIFICATION). 
 
This stage is characterized by opportunistic infection and malignancy. Other 
features are persistent and progressive constitutional symptoms, wasting disease and 
neurological disease. 
 
5.   ADVANCED HIV DISEASE (CD4 COUNT < 50 CELLS/ MM3) 46, 48 
 
Some of the infections are more frequently seen like M.avium complex, CMV 
infection, cryptococcal meningitis, histoplasmosis. CNS involvement also is very 
prominent. 
 
¾ 1993 REVISED CLASSIFICATION FOR HIV INFECTION AND 
EXPANDED CASE DEFINITION FOR AIDS IN ADOLESCENTS AND 
ADULTS.7 
CD4 cell count A B C 
> 500 / mcl (>29%) A1 B1 C1 
200-499/mcl (14% to 28%) A2 B2 C2 
<200/ mcl (<14%) A3 B3 C3 
 
CATEGORY A: 
Asymptomatic HIV infection 
Persistent generalized lymphadenopathy 
Acute Retroviral syndrome 
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CATEGORY B: 
Bacillary Angiomatosis 
Oral or recurrent Vulvovaginal candidiasis 
Cervical dysplasia 
Constitutional symptoms (fever of 38.5 C, diarrhea > 1 month) 
Oral Hairy leukoplakia 
Herpes Zoster 
Idiopathic Thrombocytopenic purpura 
Listeriosis 
Pelvic inflammatory disease 
Peripheral neuropathy 
CATEGORY C: 
(AIDS- defining conditions)  
Candidiasis of esophagus, pulmonary. 
Cervical cancer 
Coccidioidomyosis 
Cryptococcosis extra pulmonary 
Cryptosporidosis 
Cytomegalovirus infection 
Herpes simplex with esophageal, pulmonary or mucocutaneous involvement  
of > 1 month 
Histoplasmosis 
HIV encephalopathy 
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Isosporiasis 
Kaposis sarcoma 
Lymphoma 
Mycobacterium avium complex or M. kansasi 
Mycobacterium tuberculosis 
Pneumocystis carinii pneumonia 
Pneumonia, recurrent with more than 2 episodes in 12 months 
Progressive multifocal encephalopathy 
Salmonellosis 
Toxoplasmosis. 
 
LABORATORY TESTS FOR THE DIAGNOSIS OF HIV 
INFECTION 
 
1. TESTS FOR HIV SPECIFIC ANTIBODIES IN SERUM / 
PLASMA 
The test for detecting HIV specific Antibodies are divided into screening and 
supplemental tests. 
A.   SCREENING TESTS 
These tests are rapid and inexpensive serological tests, which are used for 
screening antibodies against HIV in infected individuals. 
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These tests possess high degree of sensitivity but some false positives do occur. 
Therefore, these tests are used as presumptive tests. 
Screening tests include, 
1. Enzyme linked immunosorbent Assays (ELISA) 
This solid phase assays is an extremely good screening test with a sensitivity of 
> 99.5% 
2. Rapid Tests 
These tests have a total reaction time of less than 30 mins. The results are read 
by naked eyes. 
There are several formats of rapid tests available commercially but the most 
popular ones are the dot blot assays. 
 
B.  SUPPLEMENTAL TESTS 
Detects antibodies against HIV 
These tests are recommended for validation of the positive results of the 
screening assays. 
1. Western Blot assay 
This assay takes advantage of the fact that multiple HIV antigens of different 
well characterized molecular weights elicit the production of specific antibodies. 
2. Immunofluoresence test. 
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II).   TESTS FOR HIV SPECIFIC ANTIBODIES IN SALIVA 
The Antibody assays with the class specific antibody capture format have been 
designed for testing salivary specimens for the presence of anti-HIV antibodies. 
 
Although these kits are efficacious there is some concern about how early 
during seroconversion the anti-HIV antibody is detectable in saliva as compared to 
serum following primary infection. 
 
III).   CONFIRMATORY TESTS 
These tests confirm the presence of virus in an individual who is either 
seropositive or has equivocal results from various serological tests. 
 
¾ VIRUS ISOLATION  
The virus can be isolated from blood of infected individuals by co-cultivating 
peripheral blood mononuclear cells with those of uninfected donors. 
This assay is 100% specific but its sensitivity varies with the stage of infection. 
However this procedure is labour intensive and dangerous technique, which 
could be undertaken by the specialized laboratories only. 
 
 
 
 
 28
 
 
¾ DETECTION OF HIV SPECIFIC CORE ANTIGEN (P24): 
An antigen test may be useful 
(a) During “Window Period” 
(b) During late disease when the patent is symptomatic 
(c) To detect HIV infection in a newborn 
 
This is an EIA type assay in which the solid phase consists of antibodies to the 
p24 antigen of HIV. 
 This test is relatively insensitive being able to detect 50-60 pg/ml of antigen. 
 
 POLYMERASE CHAIN REACTION (PCR): 
It is an extremely sensitive assay 
Three different techniques namely 
RT PCR, NASBA (nucleic acid sequence based amplification) 
and branched DNA (b-DNA) assay have been  employed . 
 
These tests are of value in making a diagnosis of HIV infection, in establishing 
initial prognosis and determining the need for therapy and for monitoring the effects 
of therapy. 
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¾ ANTIRETROVIRAL DRUGS 2  
Antiretroviral agents are drugs which act at various stages of the life cycle of 
HIV in the body and work by interrupting the process of viral replication.  
 
 
♣ ANTIRETROVIRAL DRUGS 
1. Nucleoside Reverse transcriptase inhibitors (NRTI) 
Zidovudine  (AZT/ ZDV) 
Stavudine  (d4T)  
Lamivudine (3TC) 
Didanosine (ddI) 
Zalcitabine (ddC) 
Abacavir (ABC) 
Emtricitabine (FTC) 
 
2. Nucleotide Reverse transcriptase inhibitors (NtRI) 
Tenofovir (TDF) 
 
3. Non-nucleoside reverse transcriptase inhibitors (NNRTI) 
Nevirapine (NVP) 
Efavirenz (EFV) 
Delaviridine (DLV) 
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4. Protease inhibitors (PI) 
Saquinavir (SQV) 
Ritonavir    (RTV) 
Nelfinavir    (NFV) 
Amprenavir (APV) 
Indinavir       (INV) 
Lopinavir / Ritonavir (LPV) 
Fosamprenavir (FPV) 
Atazanavir (ATV) 
Tipranavir (TPV) 
5. Fusion inhibitors (FI) 
Enfuvirtide (T-20) 
6. Integrase Inhibitors (New) 
7. CCR5 Entry inhibitor (New) 
Drug class Class specific Drug/s association 
strongest 
 
 
NRTIs 
Peripheral neuropathy 
Pancreatitis  
Hepatic steatosis / lactic acidosis 
Anemia / Neutropenia 
Myopathy / cardiomyopathy 
Extremity fat loss 
d4T, ddC, ddI 
ddI 
ddI, d4T 
ZDV 
ZDV 
d4T, ZDV 
 
 
PIs 
Gastrointestinal intolerance  
Fat redistribution 
Hyperlipedemia 
Insulin resistance / hyperglycemia 
Bleeding in hemophilia 
Liver enzyme derangement 
 
 
NNRTIs 
Rash / Stevens johnson Syndrome   
Hepatitis 
Nevirapine 
Nevirapine 
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GOALS OF ANTIRETROVIRAL THERAPY 2  
 
The currently available ARV drugs cannot eradicate the HIV infection from the 
human body. This is because a pool of latently infected CD4 cells is established 
during  the earliest stages of acute HIV infection and persists within the  organs / cells 
and fluids  even with  prolonged suppression of plasma viremia to < 50 copies/ml by 
ART. The goals of therapy are as follows, 
 
1. CLINICAL GOALS 
Prolongation of life and improvement in quality of life  
2. VIROLOGICAL GOALS 
Greatest possible reduction in viral load as long as possible 
3. IMMUNOLOGICAL GOALS 
           Qualititative and Quantitative immune reconstitution. 
4. THERAPEUTIC GOALS 
Rational sequencing of drugs in a fashion that achieves clinical, virological and 
immunological goals while maintaining treatment options, limiting drug toxicity and 
facilitating adherence. 
5. REDUCTION OF HIV TRANSMISSION IN INDIVIDUALS 
Reduction of HIV transmission by suppression of viral load. 
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INDICATIONS FOR THE INITIATION OF 
ANTIRETROVIRAL THERAPY IN PATIENTS WITH HIV 
INFECTION 1 
 
I  Acute infection syndrome 
II. Chronic infection 
A. Symptomatic disease 
B. Asymptomatic disease*    
1. CD4 + T cell Count <350 / mcl or decreasing 
2. HIV RNA>50,000 copies / mcl or increasing 
III. Post exposure prophylaxis 
*-This is the area of greatest controversy. 
RECOMMENDED COMBINATION TREATMENTS FOR THE NAIVE 
PATIENT * 14 
Regimen A B C 
Preferred Efavirenz 
Lopinavir/ Ritonavir 
ZDV 
Abacavir 
Tenofovir 
ddI 
3TC 
FTC 
Alternative Fosamprenavir/ ritonavir 
Saquinavir/ ritonavir 
Nevirapine ** 
  
 
*- One drug from columns A, B, and C. 
**- Only when CD4 < 250 cells / mm3 in females or 
             < 400 cells/ mm3 in males. 
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Factors to consider when choosing HAART, 
1. Ease of compliance 
2. Drugs regimen that fits the patients lifestyle 
3. Wishes of the patient 
4. Stage of disease 
5. Possibility of additive side-effects (e.g. ddI and neuropathy) 
6. Potential for drug interactions with non HIV medications 
7. Antagonistic NRTIs combinations (ZDV/ d4T and ddC/ 3TC) 
8. CNS penetration 
9. Possibility of acquisition of resistant virus. 
 
Following  the initiation of therapy one should expect a 1 log (tenfold) 
reduction in plasma HIV RNA levels within 1 to 2 months and eventually a decline in 
plasma HIV RNA level to <50 copies / ml.1 
 
During this same time there should be a rise in the CD4 + T cell count of 100 to 
150 / mcl that is particularly brisk during the first month of therapy. 
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LABORATORY MONITORING OF PATIENTS WITH   HIV 
INFECTION 
1. CD4 + T CELL COUNT 1 
The CD4 +T cell count is the laboratory test generally accepted as the best 
indicator of the immediate state of immunologic competence of the patient with HIV 
infection. 
Measurements should be performed at the time of diagnosis and every 3 to 6 
months thereafter. More frequent measurements should be made if a declining trend is 
noted. 
A significant change between 2 tests is defined as approximately 30% change 
of the absolute count and 3 % point change in CD4 percentage. 
It also assesses the need for initiating chemoprophylaxis for opportunistic 
infections. 
2. HIV RNA DETERMINATIONS 1 
 
            Plasma HIV RNA may be a consideration in the decision to initiate therapy. In 
addition, viral load is critical for evaluating response to therapy. 
 The two most commonly used techniques are the RT-PCR assay and 
 b DNA assay. 
           In most instances of effective therapy this will be <50 copies /ml. This level of 
virus is generally achieved within 6 months of the initiation of effective treatment. 
During therapy, levels of HIV RNA should be monitored every 3 to 4 months to 
evaluate the continuing effectiveness of therapy. 
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♣ HIV- RESISTANCE TESTING 
HIV resistance testing is done using two different types of assays Genotypic, in 
which the reverse transcriptase and the polymerase genes are sequenced using 
different techniques and Phenotypic, in which the HIV replication in vitro in the 
presence of antiretroviral drugs is examined. Results of resistance testing can be used 
to guide ART. 
 
♣ TB/ HIV CO- INFECTION 20 
HIV infection increases the risk of progression from latent to active TB by 
approx 100 fold. The CD4+T cell count influences both the frequency and clinical 
expression of active tuberculosis.     Tuberculosis also negatively impacts HIV 
disease. 3, 59 
           The treatment of TB in patients with HIV infection should follow the same 
principles for persons without HIV co-infection. 12 
Presence of active tuberculosis requires immediate initiation of treatment. 
In Antiretroviral-naive patients, delay of ART by 4-8 weeks after initiation of 
tuberculosis treatment permits a better definition of causes of adverse reactions and 
paradoxical reactions. 
Directly observed therapy is strongly recommended for HIV-TB co-infected 
patients. 
Despite drug interactions, rifamycin should be included in patients receiving 
ART, with dosage adjustment as necessary. 
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           Paradoxical reaction should be treated with continuation of treatment for 
tuberculosis and HIV, along with use to NSAIDs. In severe cases, some suggest use of 
high dose prednisone. 
 
¾ DEFINITIONS OF ANTIRETROVIRAL TREATMENT FAILURE 2 
Antiretroviral treatment failure can be defined as a suboptimal response to 
therapy. 
 
CLINICAL FAILURE 
New or recurrent WHO stage 4 condition, after atleast 6 months of ART. 
Immune reconstitution syndromes should be excluded. Certain WHO clinical stage 3 
conditions (e.g. Pulmonary TB, severe bacterial infections) may indicate treatment 
failure. 
 
VIROLOGICAL FAILURE 
Plasma viral load >10,000 copies /ml at 6 months after initiation of ART. 
 
IMMUNOLOGICAL FAILURE 
          Fall   of CD4 count to pre- therapy baseline (or below). 
         50% fall from the on- treatment   peak value (if known). 
        Persistent CD4 levels below 100 cells / mm3  
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POST EXPOSURE PROPHYLAXIS 1 
 Combination therapy is now recommended   for occupational   
Post – exposure (PEP) where the risk is deemed to be significant. 
 
U.S. Public Health Service Guidelines recommend, 
1)   A combination   of two NRTI’s given for 4 Wks for routine exposures or 
2)   A combination of two NRTI’s plus a third drug given for 4 weeks for high - risk        
or otherwise complicated exposures.       
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MATERIALS AND METHODS 
 
The study was conducted on 215 HIV infected adults who attended the ART 
centre, Thanjavur Medical College Hospital from January 2006 to July 2007. 
All patients were thoroughly evaluated by detailed history, appropriate 
investigations as per proforma. 
Various pre and post treatment investigation included the following, 
1 Total and Differential Count, hemoglobin, 
2. Blood Urea,  
3. Blood Sugar, 
4. Serum creatinine 
5. Serum electrolytes 
6. Liver Functions tests 
7. X ray chest. 
8. Sputum AFB, if necessary 
9. Body weight 
10. CD4 Count 
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SELECTION CRITERIA 
 
 
       The following criteria are used for selection of HIV infected patients, 
1. The diagnosis of HIV confirmed as per WHO criteria. 
2 Initiation of Treatment for HIV infected patients according to WHO criteria. 
3 Patients should be more than 14 years of age 
 
 
EXCLUSION CRITERIA 
 
1. Patients less than 14 years of age. 
2. The patients who have already received treatment with antiretroviral drugs 
outside. 
3. Patients who died within 6 months after initiation of antiretroviral therapy. 
4. Patients who lost follow-up after initiation of anti-retroviral therapy.  
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DIAGNOSTIC CRITERIA FOR HIV INFECTION 
 
National Guidelines on testing Adults 2 
 
1. For symptomatic persons. 
The sample should be reactive with two different EIA (Enzyme      
immunoassay kits) 
 
2. For asymptomatic persons. 
The sample should be reactive with three different EIA kits. 
The blood sample collected at one time is tested with the first kit. If it is 
reactive, it is then a retested sequentially with second and third kits. 
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SUBJECTS AND METHODS 
 
This prospective study was conducted at the ART centre, Thanjavur Medical 
College & Hospital from January 2006, 215 HIV positive patients enrolled in the 
centre for antiretroviral therapy were selected in order as per selection criteria. 32 
patients were excluded subsequently since they died within 6 months or lost follow-up 
after starting ART. These patients were referred for HIV care through, 
(1)  ICTC (Integrated counseling and treatment centre) 
(2)  TB  RNTCP Centre 
(3)  Outpatient department 
(4)  In-patient department  
(5)  STI clinic 
(6)  Private practitioner 
(7) Self-referred 
(8) Sex worker out reach or others. 
Efforts were made to establish the source of infection by history-taking for risk 
factor. 
(1) Heterosexual 
(2) MSM (male sex with male) 
(3) IV Drug addicts 
(4) Blood Transfusions 
(5)  Probable unsafe injection and  
(6)  Unknown 
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Educational status of the patients were enquired. History was taken regarding 
employment and occupation of the patients. 
History was obtained in detail about the marital status of the patient and other 
family members with particular attention to their HIV status. 
After receiving consent from the patients they were retested for their HIV 
status at our centre by ICTC as per National guidelines for HIV testing as mentioned 
in page no.31 
All patients were screened for opportunistic infections. Patient’s weight was 
recorded. 
The clinical staging were determined after detailed clinical examination of the 
patients. 
 
 
WHO CLINICAL STAGING OF HIV/AIDS FOR ADULTS AND 
ADOLESCENTS, 2006. 
 
 
Clinical stage 1 
Asymptomatic 
          Persistent generalized lymphadenopathy 
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Clinical stage 2 
Unexplained moderate weight loss (<10% of presumed or measured   
 body weight) 
         Recurrent respiratory tract infections 
Herpes zoster 
Angular cheilitis 
Recurrent oral ulceration 
Papular pruritic eruptions 
Seborrhoeic dermatitis 
Fungal nail infections 
 
Clinical stage 3 
 
Unexplained severe weight loss (>10% of presumed or measured 
 body weight) 
    Unexplained chronic diarrhea for longer than 1 month 
Unexplained persistent fever for longer than 1 month 
Persistent oral candidiasis 
Oral hairy leucoplakia 
       Pulmonary tuberculosis 
  Severe bacterial infections 
       Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
Unexplained anaemia, neutropenia and or thrombocytopenia 
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        Clinical stage 4  
        HIV wasting syndrome 
        Pneumocystis carinii pneumonia 
      Recurrent severe bacterial pneumonia 
        Chronic herpes simplex infection 
        Oesophageal candidiasis 
        Extrapulmonary tuberculosis 
        Kaposi sarcoma 
        Cytomegalovirus infection 
        CNS Toxoplasmosis. 
        HIV encephalopathy 
        Extrapulmonary Cryptococcosis including meningitis 
        Disseminated non-tuberculous mycobacteria infection 
        Progressive multifocal encephalopathy 
        Chronic cryptosporidiosis 
        Chronic isosporiasis 
      Disseminated mycosis (extra pulmonary histoplasmosis, coccidioidomyosis) 
        Recurrent septicemia 
        Lymphoma (cerebral or B- cell non- Hodgkin) 
        Invasive cervical carcinoma 
Atypical disseminated leishmaniasis  
Symptomatic HIV-associated nephropathy or symptomatic HIV-associated 
cardiomyopathy. 
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   As per NACO guidelines, Functional status of the patients before starting 
treatment was assessed and graded as WAB, 
 W-Working:  Able to perform usual work in or out of the house, harvest, 
normal activities of playing. 
A-Ambulatory: Able to perform activities of daily living but not able to work. 
B-Bedridden    : Not able to perform activities of daily living. 
All patients were subjected to relevant investigations as required. 
 
¾ CD4+ COUNT ANALYSIS 
           The specimens were acquired and analysed by the BD FACS count software on 
identically configured FACS Calibur flow cytometer (Beckton, Dickinson & 
company, San Jose, USA). 
 
Antiretroviral Treatment was initiated if the patients met the WHO criteria for 
starting therapy.                                       
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INITIATION OF ART BASED ON CD4 COUNT AND WHO 
CLINICAL STAGING: 2 
 
Classification of 
HIV-associated 
clinical disease 
WHO 
clinical stage
CD test not 
available (or 
result pending) 
CD4 test 
available 
Asymptomatic 1 Do not  treat 
Mild symptoms 2 Do not treat 
Treat if 
CD4 < 200/ µl 
Advanced 
symptoms 
3 Treat 
Consider treatment if 
CD4 <350/µl and 
initiate ART before 
CD4 drops below 200/ 
µl. 
Severe/ Advanced 
symptoms 
4 Treat 
Treat irrespective of 
CD4 count 
 
     The First line Antiretroviral drug regimens used are, 
(1) Stavudine + Lamivudine + Nevirapine   
(2) Stavudine + Lamivudine + Efavirenz 
(3) Zidovudine + Lamivudine + Nevirapine  
(4) Zidovudine + Lamivudine + Efavirenz 
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Tuberculosis infection was specifically investigated and if found positive was 
treated with TB regimens as per RNTCP guidelines after getting registered in TB 
centre, Thanjavur Medical College Hospital. 
 
STATISTICAL ANALYSIS 
 
 
The statistical analyses for assessing the significance value of variable were 
done using Paired samples “T” test and Sign Test. 
 
 
TREATMENT FOLLOW-UP 
 
 
  After 6 months of initiating therapy, patient was examined in detail for change in,  
Body weight 
Functional status of the patient 
Clinical staging as per WHO 
Opportunistic infections  
CD 4 count. 
If patient died after initiating therapy, enquiry was made into the cause of Death. 
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RESULTS AND 
OBSERVATIONS 
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RESULTS AND OBSERVATIONS 
 
This study was conducted among 215 patients attending ART centre, at 
Thanjavur Medical College, Thanjavur with the aim of analysing immunological and 
clinical response to antiretroviral therapy. 
The analysis revealed the following interesting results as found out among the 
study population of 183 patients. 
1. AGE DISTRIBUTION 
Fig -1 
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Age Range – 20 years to 70 years 
Mean and Median: 35 years.  When age distribution was analysed, most of them 
belonged to the most productive age group of 20-40 years (80%). This shows that HIV 
prevalence is high among younger age group (Fig 1). 
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2. SEX DISTRIBUTION 
Table -1 
Sex Frequency Percent 
Male 104 56.8 
Female 79 43.2 
 
There  was an increased prevalence of HIV among males when compared to 
females. 
3. RISK FACTORS FOR HIV TRANSMISSION 
Fig – 2 
 
Risk factors
Heterosexual
IDU *
Blood Transfusion
Unknown
Heterosexual and Blood
Transfusion
 
 
*IDU – I.V. Drug Abuse. 
 
When risk factor for HIV transmission were analysed the most common risk 
was Heterosexual route of transmission (Figure: 2). 
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4. EDUCATION 
Table – 2 
  
EDUCATIONAL LEVEL FREQUENCY PERCENT 
Non - literate 31 16.9 
Primary school 84 45.9 
Secondary school 58 31.7 
College & Above 10 5.5 
 
Education and literacy status had an impact on HIV transmission since most 
of them had only school education (77.6%). Table – 2 
 
 
5. EMPLOYMENT 
Table-3 
 
Employed Percent 
Yes 58 
No 42 
 
Among our study subjects 58% were employed. 
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6. MARITAL STATUS 
Table -4 
 
MARITAL STATUS FREQUENCY PERCENT 
Single 22 12 
Married 117 63.9 
Widow 37 20.2 
Separated 7 3.8 
 
When marital status was analysed most of them were married (63.9 %). 
 
 
7. ANY FAMILY MEMBERS AFFECTED 
Table -5 
FREQUENCY PERCENT 
Yes 48.6 
No 51.4 
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8. ART REGIMEN 
Fig - 3 
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Regimens include 1- STV+ LMV + NVP 
2- STV+LMV + EFV 
3. ZDV + LMV +NVP 
4. ZDV+ LMV + EFV 
5. Change of regimen within above categories    
           during treatment. 
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9. TUBERCULOSIS AND HIV 
Table - 6 
TB FREQUENCY PERCENT 
Pulmonary  28 15.3 
Extra pulmonary 8 4.4 
No 147 80.3 
 
All patients diagnosed to have Tuberculosis were initiated on cat I ATT except 
two patients who were started on cat II ATT.  
 
10. ASSESSING FUNCTIONAL STATUS IMPROVEMENT TO ART. 
                                           Fig - 4 
ASSESSING FUNCTIONAL  STATUS  IMPROVEMENT 
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* Discussed in Page no. 36 
There was a significant improvement in functional status of the patients after 
starting treatment. 
The Functional status improvement after institution of treatment as evidenced 
by change in the level of functional status class is statistically significant with  
P value < 0.05. 
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11.   FUNCTIONAL STATUS OBSERVATION AMONG TB PATIENTS 
WITH HIV:   
                                             Table - 7                                       
FUNCTIONAL STATUS PRE ART POST ART 
W 7 30 
A 29 6 
B - - 
 
                   All figures are in numbers. 
 The change in functional status level in TB patients, who received 
antiretroviral therapy, is statistically significant with P Value < 0.05. (Table- 7) 
12. OBSERVATION OF CLINICAL RESPONSE TO ANTIRETROVIRAL 
THERAPY BASED ON WHO CLINICAL STAGING. 
Fig – 5 
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The clinical improvement seen after  treatment  as evidenced  by  transition in clinical  
staging is statistically  significant with  P value  < 0.05 ( Fig – 5 ) 
 57
13. OPPORTUNISTIC INFECTIONS 
                                                        
                                                           Table - 8 
 
Opportunistic Infections  Before ART After ART 
Yes 89 5 
No 94 178 
  
Figures are in numbers. 
Statistically significant  P value < 0.05. 
 
14. ASSESSING CLINICAL RESPONSE BY MEASURING CHANGE IN 
WEIGHT TO THE ANTIRETROVIRAL THERAPY:  
     
Table 9 
 
 
 PRE- ART 
WEIGHT 
POST ART 
WEIGHT 
MEAN 46 kgs 50 kgs 
MEDIAN 45 kgs 50 kgs 
STD DEVIATION 7.88 8.39 
STD ERROR OF MEAN 0.58 0.62 
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STASTICAL ANALYSIS: 
 
 
   Paired samples “T” test: 
Table - 10 
 
Paired Differences 
99% confidence 
interval of the 
difference 
 
 
Pair Mean S.D 
S.E. of 
mean 
Lower Upper 
Significance  
(2 tailed) 
p value 
Pre-
ART 
Wt - 
Post 
ART wt 
 
-4.79 
 
4.35 
 
.3219 
 
-5.63 
 
-3.95 
 
< 0005 
 
The change  in  weight  on treatment , as measured by Paired sample  “T” test  
is statistically  significant  with    P  value  < 0.0005 (99% C.I ) 
SIGN TEST: 
The sign test   determines the actual number of pairs with the negative 
difference, Positive difference and no change (Ties). The statistical significance is also 
calculated by “Z” score and P value. 
Table 11  
 Frequencies No 
Negative Difference (a)  9 
Positive Difference (b) 159 
Ties  (c ) 15 
 Post ART wt 
-Pre ART WT 
Total 183 
 
A.  post ART wt   < pre ART wt 
B.  post ART wt   > pre ART wt 
C.  pre ART wt = post ART wt 
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TEST STATISTICS 
Table – 12 
 
 Post  ART WT- 
Pre ART WT 
Z -11.496 
Asymp sig (2.tailed) <.0005 (p value) 
 
15. WEIGHT INCREMENT RECORDING: 
Fig - 6 
 
 
WEIGHT  INCREMENT  RECORDING
1.6 11.5
42.1
29.5
9.3
4.4 1.6
< - 10%
  10 to 0%
0 to 10%
10 to 20%
20 to 30%
30 to 40%
40 to 50%
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16. COMPARISON OF SEX WITH WEIGHT INCREMENT: 
 
Table – 13 
 
Weight increment (%)  
        Sex < 0 0 – 20       20 – 50  
 Male  15 70 15 
Female 10 74 16 
                
                All figures are in percentage. 
 
               The sex does not have any influence on the weight increment as evidenced in 
the above table. 
 
17.   ASSESSING IMMUNOLOGICAL RESPONSE TO ART BY MEASURING 
CD4 COUNT: 
                                                        
Table- 14 
 
 Pre ART CD4 Post ART CD4 
Mean 141 359 
Median 123 356 
Std Deviation 89.87 148 
Std Error  of  mean 6.64 10.94 
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STATISTICAL ANALYSIS: 
Paired samples “T” test 
     Table 15 
Paired  Differences 
99% confidence 
Interval of the 
Difference 
 
PAIR  
Mean 
 
S.D 
 
S.E 
Lower upper 
 
Significance 
(2 tailed) 
P value 
 
 
Pre-ART CD4 
-post ART CD4 
 
-217 
 
126 
 
9.37 
 
-242 
 
-193 
 
<.0005 
 
   
           The  statistical  analysis   done  by using  paired sample  “T”  test shows  the 
change  in  CD4  count  to  antiretroviral  therapy is  statistically   significant , with  
 P. value < 0.0005    (99% CI) 
SIGN TEST: 
                                                    Table - 16 
 Frequencies No 
Negative Differences (a) 5 
Positive Differences (b) 178 
Ties  (c) 0 
 
 Post  ART CD4 
- Pre  ART CD4 
Total 183 
 
a. Post  ART CD4 < Pre  ART  CD4 
b. Post ART  CD4 > Pre  ART CD4 
c. Pre ART CD4 = Post ART CD4. 
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TEST STATISTICS 
 
Table – 17 
 
 Post ART CD4 
-Pre ART CD4 
Z -12.71 
Asymp. Significance < 0.0005 ( p-value ) 
 
Sign test also reveals the difference in CD4 count to be statistically 
significant (P Value < 0.0005). 
 
18. CD4 INCREMENT RECORDING: 
                                                        Fig - 7 
 
CD4 INCREMENT  RECORDING (PERCENT)
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19. COMPARISON OF SEX WITH CD4 INCREMENT: 
                                                      Table - 18. 
 
Sex  
CD4 Increment Male Female 
-100 to 0 1.9 3.7 
0 to 100 29 34.2 
101 to 200 19.2 20.2 
201 to 300 17.3 19 
301 to 400 11.5 5.2 
401 to 500 6.7 6.3 
> 500 14.4 11.4 
 
All figures are in percentage. 
        As evidenced in the above table, sex does not influence the immunological 
response to treatment. 
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20. IMMUNOLOGICAL RESPONSE TO ART AMONG TUBERCULOSIS 
PATIENTS: 
Table 19 
 
PRE- ART CD4 POST-ART CD4  
< 200 > 200 < 200 >200 
TB 
PATIENTS 
32(88.9%) 4(11.1%) 9(25%) 27(75%) 
NON TB 
PATIENTS 
106(72%) 41 (28%) 19 (13%) 128(87%) 
 
The response in TB patients receiving ART was higher (64% increase) 
compared to the non-TB Patients (59% increase). 
 
21. DEATH AMONG PATIENTS STARTED ON ART: 
Table - 20 
Death Freq. Percent 
Yes 3 1.6 
No 180 98.4 
  
Among 215 patients started on ART in this study, 3 died after completing 6 
months of therapy and 17 died within 6 months of therapy. 
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ANALYSIS AND DISCUSSION 
 
 
1. AGE AND SEX INCIDENCE: 
In this study, the age of the patients varies from 20 years to 70 years. The study 
group comprised 104 males and 79 females (56.8% and 43.2 % respectively)   
TABLE- 1. 
Majority of patients belonged to the most productive age group of 20-40 years 
(80%) FIG - 1. As per the census 5, 39 regarding age distribution of AIDS cases in 
India, majority of HIV infections (88.59 %) are in age group of 15-49 years, out of 
which 31.8 % are in the age group of 15-29 years. 
The predominance of the males over the females is similar to the census 
statistics of AIDS cases in India. 
 
2. RISK FACTORS FOR HIV TRANSMISSION. 
In this study, the predominant route of transmission of HIV is through unsafe 
sexual practice which accounts for 84% of cases. FIG - 2. 
In Census regarding route of Infection in India, August 2006, the sexual 
transmission is responsible for 85% cases. 5, 39 
Since we have not included pediatric population in this study, the vertical 
transmission route could not be estimated, which is the next common mode of 
transmission as per census. 
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3. EDUCATIONAL LEVEL: 
In this study, majority of patients belonged to primary and secondary school 
level of education (77%). TABLE- 2. 
The incidence is less among those with higher education (5.5%) because of 
their awareness of safe sexual practices using preventive methods. 
 
4. EMPLOYMENT : 
In this study, employed patients (58%) have acquired the disease. No notable 
differences between the two groups were observed. TABLE-3. 
 However, impoverished, unemployed, underemployed mobile and migrant 
youth are particularly vulnerable to HIV, as they are less likely to have information 
about HIV or access to preventive measures, and they may face repeated risks of HIV 
infection. 
5. MARITAL STATUS. 
In this study, the majority of patients belonged to married category (63%) Also 
the widow population contributed to 20% of cases. TABLE-4. 
In nearly, half of the affected patients other members of their family were also 
affected. TABLE-5. This gives importance of preventive measures aimed at stopping 
the transmission between the couples through education and adoption of safe sexual 
practices. 
6. ART REGIMENS: 
The category 1 regimen accounts for 49% and category 3 accounts for 17.5%. 
The change in regimens cat 5 (as in table) accounts for 32%. FIG -3. 
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This is due to the substitution of Efavirenz for Nevirapine in cases of 
intolerance to the latter or if patients are receiving rifampicin- containing anti- TB 
treatment. 
In this study the stavudine based ART regimen is often preferred to zidovudine 
based ART while on initiation because of co-existence of anemia in many patients 
making them unsuitable for zidovudine based regimen. 
 
7. TB AND HIV 
 In this study, pulmonary TB (15% of patients) and Extra pulmonary TB (4.4% 
of patients) were diagnosed. They were the second most common opportunistic 
infection among patients, next to candidiasis. TABLE-6. 
 These patients were initially started on ATT and ART started subsequently 
after 2 weeks to 2 months as soon as TB treatment is tolerated. 
 
8. ASSESSING FUNCTIONAL STATUS IMPROVEMENT TO ART: 
The functional status of an individual is divided into three grades according to 
NACO, Ministry of Health and Family welfare, Government of India. 
W- Able to perform usual work. 
A- Able to perform activities of daily living but not able to work 
B- Not able to perform activities of daily living. 
In this study, there is an improvement in functional status level in response to 
ART as evidenced by an increase in patients belonging to “W” class from 49 % to 
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91% after treatment and decrease in patients of “A” class from 50% to 8% after 
treatment. FIG-4. 
This change in class is statistically significant with ‘P’ value < 0.05. 
The similar observation is also seen in patients suffering from                      
Tuberculosis with HIV. TABLE -7.    
 
9. ASSESSMENT OF CLINICAL RESPONSE TO ART BASED ON WHO 
CLINICAL STAGING. 
 
The HIV related clinical events in Adults and adolescents were classified into 
clinical stage 1 to 4 according to WHO, 2006. See page no.33 
In this study there is marked clinical improvement after ART. This is reflected 
by the following observations.  FIG - 5 
 There is an increase in clinical I stage from 2.2% to 25% and clinical II stage 
from 9% to 66%. 
 The clinical II stage increase is mainly due to the patients who had improved  
in the clinical status from stage III to stage II. 
Most important observation is the decrease in stage III from 82% to 7% after 
treatment.  
All the changes are statistically significant with P value < 0.05. 
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10. OPPORTUNISTIC INFECTIONS : 
The most common opportunistic infection observed in this study are 
candidiasis and tuberculosis. 
In this study, the opportunistic infections were seen in 89 patients before 
treatment and reduced to 5 patients after treatment. TABLE-8. 
           This is statistically significant with P value  < 0.05. 
 
11. ASSESSING CLINICAL RESPONSE BY MEASURING CHANGE IN 
WEIGHT TO ART. 
         In this study, the average pre-ART weight is 46 kg, which increased to 50 kg 
after ART. So an average of 4 kg increase in weight is seen among the study group. 
On analysing statistically with paired “T” test and sign test, showed a high 
statistical significance with P value < 0.0005, Z score – 11.496. TABLE-10, 11, 12. 
13% of patients declined in weight after ART. 
However, majority 71% showed an increment of 0-20 % after ART. FIG – 6. 
 
12. ASSESSING IMMUNOLOGICAL RESPONSE TO ART BY MEASURING 
CD4 COUNT AT END OF 6 MONTHS: 
 In this study, the mean CD4 count has increased from baseline                       
141 cells / mcl to 359 cells/ mcl after 6 months of ART.  TABLE-14. 
  The average increase in CD 4 count was 217 cells / mcl. 
            The statistical analysis done using paired ‘T’ test and sign test showed a   
Statistical significance, with P Value < 0.0005 and Z score – 12.71. TABLE-15. 
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              2.7% of patients (5 in number) showed a decline in CD4 count after 
treatment. 
            Majority of the patients (31%) showed a 0-100 % increment in CD4 count. 
  13% of patients (24 in number) showed an increase of >500 % CD4 count 
compared to baseline. FIG - 7 
  Immunological failure according to WHO in this study was seen in 2.7 % of 
patients.            
   Study by Kilaru KR et al (2006) 29 had Immunological success around 80%.  
18% had increase in CD4 by more than 200 cells, with a median CD4 increase of 114 
cells / mcl. 
            Study by Smith CJ et al (2004) 49 demonstrated a median CD4 increase of 114 
cells / mcl and Immunological success in 84% patients. 
Vajpayee et al55 showed an increase of CD4 count from a median  
179 cells / mcl to 256 cells / mcl after HAART for a period of 6 months. 
 
 SUCCESS AND FAILURE OF TREATMENT 
Both success and failure of treatment can be evaluated using different criteria - 
virological, immunological and clinical. Of these the earliest indicator is virologic 
success or failure. This is followed, often a little later, by immunological treatment 
success or failure and then clinical treatment or failure. On the other hand success of 
treatment may be seen much earlier, many patients suffering from constitutional 
symptoms rapidly improve on HAART. 
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 IMMUNOLOGICAL TREATMENT FAILURE AND SUCCESS 
Immunological treatment success is generally defined as an increase in the 
CD4 +T cell count. Failure is usually described as the absence of an increase or as a 
decrease in the CD4 +T cell count in patients receiving HAART. 
As with the decrease in viral load, the increase in CD4 + T cell count also 
occurs in two phases. Usually rapid increase occurs in the first three to four months, 
further increase is considerably less pronounced.  
The  lower the CD4 +T cell count at baseline the less likely it is to normalize 
completely (Valdez  2002, Kauffman 2003+2005) 56,27,28 
Immunological treatment success is not necessarily linked to maximal viral 
suppression; even partial suppression can result in improved CD4 +T cell count 
(Kauffman 1998 26, Mezzaroma 1999 34, Lederberger 2004 31). Virologic success is 
more appropriate for judging the efficacy of superior regimens. 
Once CD4 + T cells have normalized and plasma viremia remains undetectable, 
it is unlikely that they will reduce significantly (Philips 2002) 41 
 
 DISCORDANT RESPONSE 
Failure to achieve every one of the Therapeutic goals - clinical, immunological 
and virological is referred to as a discordant response. 
 
Some patients may have virological treatment success without immunological 
improvement. (Piketty 1998 42, Renaud 1999 47, Gabrar 2000 50, Piketty 200143). 
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The risk factors for a lack of immunological treatment response include age, 
low CD4 + T cell counts at baseline, as well as having low viral loads at the start of 
treatment (Florence 200316, Kauffmann 200528), patients who are I.V., drug users 
(Dragsted 200413), concomitant immuno-or myelosuppressive therapies. 
 
13. GENDER AND IMMUNOLOGICAL RESPONSE 
In this study gender does not show any difference in the outcome/ 
immunological response. TABLE-13, 18. 
          Studies by Kilaru KR et al (2006) 29, Smith CJ et al 47, L Fardet et al (2006) 32 
also demonstrated that the age, gender risk group does not influence the treatment 
outcome. 6, 8,11,21,44 
          However Manfredi et al 33, Sophie Garber et al (2004)50 showed that older age 
group patients have favorable immunological responses to HAART. However their 
CD4 cell reconstitution is significantly slower than in younger patients despite a better 
virologic response 18.  
 
14. IMMUNOLOGICAL RESPONSE IN TB PATIENTS 
In this study, the immunological responses seen in TB patients with HIV (64%) 
were higher as that of non- TB patients (59%) receiving ART. TABLE-19. 
Vajpayee mathu et al 55 showed that there is no difference in treatment outcome 
between TB and non- TB patients. 
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   The study by Hungchienching et al (2003) 24 demonstrated similar clinical, 
Immunological and virological responses to HAART and prognosis of HIV-1 infected  
TB patients who were concurrently treated with ART & HAART with those of non 
TB patients. 
 
Hence the treatments of opportunistic infections like TB may not only slow the 
progression of HIV disease in patients dually infected with HIV and TB but may also 
be beneficial for patients facing a high risk of imminent death due to TB in developing 
countries like India. 
 
15. DEATH AMONG PATIENTS STARTED ON ART 
Initially 215 patients were selected for study and started on ART, in this group 
17 patients died before completion of 6 months of ART, and 3 patients died after 
completion of 6 months of ART. TABLE-20. 
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CONCLUSION 
 
1.  Majority of HIV Patients belonged to the economically productive age group 
of 20-40 years. 
2. A High rate of Immunological response was observed after 6 months of   
HAART. 
3. Institution of HAART was associated with a favorable clinical response. 
4. Improvement in functional status level was observed among the HIV patients 
after 6 months of HAART. 
5. The Immunological and clinical response to HAART in HIV infected TB   
patients were similar to those of non – TB patients. 
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PROFORMA 
 
STUDY OF TREATMENT OUTCOME OF  ADULT 
HIV PATIENTS ATTENDING ART CENTRE, THANJAVUR 
 
1. Name    :     ___________ 
2. Age    :     ___________ 
3. Sex    : M/F    ___________ 
4. Place    :     ___________  
5. Date  confirmed HIV Test :     ___________ 
6. Place of HIV test   :     ___________ 
7. Entry point   :     ___________ 
8. Personal  History:- 
 
      Risk factor of HIV:-   
 a)Hetero Sexual   b)IDU      c)Blood Transfusion    ___________   
 d)Mother of child  e)Probable unsafe inj  f)Unknown. 
9. Education:-      
 
 a)Non- literate   b)Primary school   c)Secondary school   ___________   
 d)College & above 
 
10. Employed   : Y/N       Occupation  :    ___________ 
 
 
11. Family   History:      
 
a)  Single/   b) Married /  c) Widowed /   d)Divorce /  separate  ___________ 
 
 
Family members:-      
Partner / Children Age/ sex HIV 
+/- 
/ Unknown 
ART 
Y/N 
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12. Clinical and lab invg :  
          
CD4 Count 
Date WHO ClinicalStage Wt Ht 
Functional  
Status 
[WAB] 
No % 
At start ART        
At 6 months of ART        
 
 
13.  Antiretroviral   Treatment (Summary) 
       Treatment Started     a) STV + LMV + NVP   ___________ 
   
   b) STV + LMV + EFV     
 
   c) ZDV+ LMV + NVP 
 
   d) ZDV + LMV + EFV 
 
Substitution if any: 
14. TB treatment during HIV care: 
 
 Disease class:      ___________  
 TB Regimen :      ___________  
 
15. Reasons for stopping ART: 
 
a)Death  b) Transferred out  c)On medical advice     ___________  
d) Lost- to- follow up (  > 3 months ) 
 
16. Patient follow up: 
 
     CD4 Date of 
visit 
Date of  
next 
visit 
Wt Functional
Status  
WAB] 
WHO 
Clinical 
stage 
OI Antiretroviral 
Drugs 
prescribed 
TB 
 
Treatment 
ART 
s/e No % 
 
 
 
 
 
 
 
 
 
 
 
          
 
Tuberculosis Weight Functional status 
WHO clinical 
staging 
CD4 
count 
Sl.no Name ART No Age 
S
e
x 
Risk 
factor Education 
Employed 
Y/N 
Family 
H/o 
Family 
Members 
Affected 
Y/N 
ART 
Regimen  Class 
 
Regi
men 
Pre 
ART 
Post 
ART 
Pre 
ART 
Post 
ART 
Pre 
ART 
Post 
ART 
OI Pre 
ART 
Post 
ART 
1 Selvam 1 45 M HS SS Y M N A - - 50 54 A W III II oc 275 415 
2 Kumar 2 31 M HS SS N M Y A - - 50 52 A W II II - 65 292 
3 Ilanjiyam 5 29 F HS PS Y W N B,A P I 40 42 A W IV I oc 61 251 
4 Veerapandiyan 6 40 M HS,B PS Y M N A - - 50 60 W W III III oc 52 367 
5 Balakrishnan 7 32 M HS SS Y M Y A - - 54 57 A W III II - 83 302 
6 Raju 10 47 M HS SS Y M N A - - 50 57 A W III I oc 83 235 
7 Kalarani 11 38 F HS NL N W N A,B - - 36 48 A W III I oc 61 458 
8 Ganesan 12 46 M HS SS Y M Y A,D - - 38 40 A W III II - 140 146 
9 Ramesh 15 27 M HS SS Y S N A - - 45 55 A W III I - 148 173 
10 Solayan 18 32 M UK SS Y M Y A - - 42 45 W W II I - 36 824 
11 Muthukrishnan 20 49 M HS SS N M Y B P I 37 46 A W IV II oc, tb 20 225 
12 Indira 21 37 F UK SS Y M Y A - - 47 53 W W I I - 91 477 
13 Amutha 22 33 F HS PS N W N A,B P I 62 66 W W III III oc,tb 20 160 
14 Papathi 23 25 F HS SS Y W N A - - 51 51 W W III II - 82 297 
15 Indirani 24 40 F UK NL N W N A - - 35 43 A W III I oc 244 477 
16 Savariyammal 25 55 F HS SS N W N A,B P I 45 50 A W III II oc,tb 153 490 
17 Murugan 26 29 M HS PS Y M Y A,C - - 45 45 W W III II - 85 215 
18 Mathialagan 27 32 M B CL N M Y A - - 40 45 A W III II oc 32 149 
19 Suseela 28 50 F UK SS N M Y A - - 45 50 W W III II - 133 504 
20 Senthil kumar 31 31 M HS SS Y M Y A - - 50 53 W W III I - 34 120 
21 Shanmugam 33 35 M UK SS Y S N A - - 44 54 W W III I - 92 468 
22 Banumathy 35 35 F HS NL N M Y A - - 35 41 A W I I - 89 317 
23 Jeyaraman 37 35 M HS,U NL N M Y A - - 40 40 A A I I - 284 538 
24 Pandiyan 38 38 M HS PS Y M Y A,B P I 50 55 A W III II oc,tb 16 133 
25 Shanthi 39 30 F UK PS N M Y A - - 36 50 A W III I - 33 457 
26 Pattu 40 50 F HS PS Y W N A - - 51 58 A W II I - 104 419 
27 Kumar 43 38 M HS PS Y M Y A - - 55 43 W W I I - 241 375 
28 Meenatchi 44 24 F HS PS N M Y A - - 40 42 W W II I - 160 351 
29 Chitra 42 32 F UK PS Y W Y A - - 44 49 W W III I oc 339 385 
30 Murugaiyan 46 27 M HS SS Y M N A - - 39 45 W W III I oc 14 165 
31 Shahul hameed 47 34 M HS PS Y M N A,B P I 47 54 A W III I tb 59 301 
32 Govindaraj 49 40 M HS SS Y M N A,B P I 43 57 A W III II oc,tb 65 271 
33 Anbu 51 28 M B SS Y M N A - - 40 40 W W II I - 100 413 
34 Govindaraj 56 55 M IDU PS N M N A - - 55 61 W W II II oc 109 327 
35 Vijayarani 57 35 F IDU SS N M Y A - - 45 45 A A II I - 83 297 
36 Selvaraj 58 48 M IDU SS Y M N A - - 50 57 W W III III - 52 232 
37 Kumar 59 36 M HS SS N M Y A,C - - 43 49 A W III II - 30 253 
 
 
Tuberculosis Weight Functional status 
WHO 
clinical 
staging 
CD4 
count 
Sl.no Name ART No Age Sex 
Risk 
factor Education 
Employed 
Y/N 
Family 
H/o 
Family 
Members 
Affected 
Y/N 
ART 
Regimen  
Class 
 
Regimen Pre ART 
Post 
ART 
Pre 
ART 
Post 
ART 
Pre 
ART 
Post 
ART 
OI 
Pre 
ART 
Post 
ART 
38 Mani 60 27 M HS PS Y M Y A,B EP I 53 65 A W III I oc,tb 68 388 
39 Senthil kumar 62 32 M HS PS Y M Y C - - 64 62 W W III I - 336 650 
40 Perumal 63 49 M HS PS Y M N A,B P I 45 47 A W III II tb 70 203 
41 Devagi 65 37 M HS PS N SP Y A - - 39 45 A W III I - 175 170 
42 Sararfunisha 66 33 F B SS N M N A - - 38 40 A W III II oc 48 614 
43 Parameswari 67 25 F UK PS N M Y A - - 40 38 A W III II oc 171 505 
44 Subramaniyam 68 29 M HS PS Y M Y A - - 45 44 W W III III - 199 187 
45 Vasantha 70 30 F UK PS N W Y A - - 50 57 A W III II oc 279 451 
46 Pilavendran 72 38 M HS NL Y M N A - - 47 50 W W III II - 182 248 
47 Sivaji 73 32 M HS PS Y M N A - - 50 53 W W III II - 128 254 
48 Durairaj 75 37 M HS PS Y SP Y A - - 34 36 A W III II oc 60 205 
49 Elancheran 76 49 M HS SS Y M Y A - - 45 47 A A III II oc 86 128 
50 Muthukumaran 78 30 M B SS N S N A - - 45 59 A W III I - 61 444 
51 Malar 80 28 F UK PS N M Y A - - 48 48 W W III I - 269 373 
52 Elangovan 82 37 M HS PS N M N B,A EP I 51 55 A W IV III tbm 137 265 
53    Janaki 86 45 F HS,B PS N W N A - - 44 48 A A III III - 89 164 
54 Sumithra 87 30 F HS,B PS N M Y B,A P I 30 40 A W II I oc,tb 96 446 
55 Chitradevi 89 30 F UK PS N M N A - - 33 45 B W IV III oc 12 315 
56 Thiruvengadam 96 25 M HS PS N S N A - - 40 50 A W III I - 89 176 
57 Malar 113 40 F HS NL N W Y A - - 32 36 W W IV II - 61 353 
58 Moorthy 114 30 M HS CL Y M N C - - 48 70 A W III I oc 44 284 
59 Saravanan 116 27 M HS SS Y S N C - - 47 47 A W III II - 176 312 
60 Karunanithi 118 43 M HS SS N M N C,D - - 54 52 A A III II oc 285 360 
61 Indirakumar 119 37 M HS PS Y M Y C - - 45 49 A W III II oc 75 370 
62 Ananthi 121 26 F HS PS Y W Y A - - 35 42 W W III II - 23 318 
63 Ponnuswamy 124 37 M HS PS Y M N C - - 50 61 W W III II oc 96 152 
64 Ravikumar 127 35 M HS CL Y M Y C - - 43 45 W W III II - 97 369 
65 Viswanathan 130 28 M HS SS N S N C,D EP I 60 67 W W III II tb 333 639 
66 Ilayaraja 131 25 M HS PS Y S N C - - 48 57 W W III II - 61 252 
67 Parvathy 132 40 F HS NL N W Y A - - 38 38 W W III II oc,tb 212 258 
68 Shakila banu 133 24 F HS PS N W Y A - - 48 50 W W III II - 238 400 
69 Kamalakannan 136 37 M HS PS Y M N C - - 54 56 A W IV I oc 295 598 
70 Nagarajan 138 41 M HS PS Y M N A - - 41 45 W W III II - 49 261 
71 Arokiyaraj 139 36 M HS SS Y M Y A - - 38 47 A W III II oc 167 719 
72 Kannagi 141 36 F HS SS N W N A - - 48 52 A W III II - 123 440 
73 Selvi 142 40 F HS PS N W Y C - - 50 55 W W III II - 292 389 
74 Ramaswamy 143 70 M B PS Y M Y A - - 50 56 A W III II oc 21 152 
 
 
Tuberculosis Weight Functional status 
WHO 
clinical 
staging 
CD4 
count 
Sl.no Name ART No Age 
S
e
x 
Risk 
factor Education 
Employed 
Y/N 
Family 
H/o 
Family 
Members 
Affected 
Y/N 
ART 
Regimen  
Class 
 
Regi
men 
Pre 
ART 
Post 
ART 
Pre 
ART 
Post 
ART 
Pre 
ART 
Post 
ART 
OI 
Pre 
ART 
Post 
ART 
75 Deenadayalan 147 47 M HS SS Y M N C - - 53 65 W W III II - 271 405 
76 Rajakumar 149 35 M HS PS N S N C - - 64 62 W W III I - 54 254 
77 Rajendran 150 44 M HS SS Y M N A - - 45 47 A A IV II oc 13 134 
78 Senthikumar 153 31 M HS PS N M Y C - - 39 45 W W III I - 220 478 
79 Chitra 155 26 F HS NL N M Y C - - 38 40 W W III II - 184 170 
80 Sumathi 156 33 F HS SS N W Y C - - 40 38 W W III II - 141 333 
81 Lakshmi 157 30 F HS PS N M N C - - 45 44 A A III II oc 244 354 
82 Nageswar 158 22 F HS PS Y W Y C,A - - 50 57 W W III II - 116 362 
83 Banumathy 159 30 F HS PS N M Y A,C - - 47 50 W W III II - 265 413 
84 Thirunavukaras 160 33 M HS PS Y S N C - - 50 53 W W III III - 191 596 
85 Vasanthi 161 30 F HS NL Y M Y C - - 34 36 W W III III - 154 284 
86 Dhanalakshmi 162 30 F HS NL Y SP N A - - 45 47 W W III II - 296 671 
87 Veeraragavan 164 24 M HS PS N S N C - - 45 59 A W III II oc 257 440 
88 Subramaniyan 167 29 M HS PS Y M Y D,C P I 48 48 A W III II oc,tb 75 142 
89 Jaithunbibi 168 30 F HS NL Y SP N C,A - - 51 55 W W III II oc 273 454 
90 Kasthuri 171 22 F HS NL Y S N A - - 44 48 W W III II oc 193 686 
91 Ahamed 174 38 M HS CL N M N C,D EP II 30 40 A W IV II oc,tbl 242 387 
92 Mathi 175 35 M HS NL Y M Y C - - 33 45 W W III I - 248 578 
93 Vellayammal 176 30 F HS NL N M Y A - - 40 50 A W III II oc 68 203 
94 Vasantha 177 40 F HS PS Y W Y A - - 32 36 A W III II - 237 647 
95 Melen latha 178 30 F HS SS N M Y A,B - - 48 70 W W III II - 210 468 
96 Parvathy 181 37 F HS M PS N M A,B P I 47 47 A A III IV oc,tb 36 18 
97 Muthulaxmi 183 35 F HS NL Y M Y A - - 54 52 A W III II - 240 435 
98 Latha 191 29 F HS PS Y M Y A,B - - 45 49 W W III II - 194 251 
99 Jeyalakshmi 192 65 F UK CL N W N A - - 35 42 A W III III - 258 478 
100 Periyaswamy 193 35 M HS NL N M Y C - - 50 61 A W III II - 113 356 
101 Suseela 194 25 F HS SS N M Y A - - 43 45 A W III II - 102 527 
102 Ananthi 195 35 F HS PS N W N C - - 60 67 W W III I - 101 346 
103 Javomary 196 26 F HS PS N M Y A - - 48 57 W W III II - 254 529 
104 Srinivasan 199 33 M HS CL Y M N C,A - - 38 38 W W III II - 251 557 
105 Rajendran 200 38 M HS PS Y M N A,B P I 48 50 A W III II tb 277 435 
106 Rajan 203 32 M HS PS Y M N C P I 54 56 W W III II tb 153 411 
107 Maruthavanan 204 48 M HS SS Y M N D,C EP I 41 45 A A IV III tb 127 171 
108 Chellapan 205 40 F HS NL N M N A - - 38 47 A W III I - 104 318 
109 Rani 206 45 F HS PS N S N B,A P I 48 52 A W III I oc,tb 100 356 
110 Vijayakumar 207 30 F HS SS Y M N B,D EP I 50 55 W W II I oc,tbl 77 230 
111 Mullayammal 208 35 F HS NL Y W Y A - - 50 56 A W III II - 345 393 
 
 
Tuberculosis Weight Functional status 
WHO 
clinical 
staging 
CD4 
count 
Sl.no Name ART No Age 
S
e
x 
Risk 
factor Education 
Employed 
Y/N 
Family 
H/o 
Family 
Members 
Affected 
Y/N 
ART 
Regimen  
Class 
 
Regi
men 
Pre 
ART 
Post 
ART 
Pre 
ART 
Post 
ART 
Pre 
ART 
Post 
ART 
OI 
Pre 
ART 
Post 
ART 
112 Karunanithi 209 51 M HS CL N M N A - - 30 45 B A IV II Pcpcmv 271 405 
113 Muthukumaran 210 32 M HS PS Y M N C,B P I 50 54 A W III I tb 54 254 
114 Ammakannu 212 32 F HS SS N SP Y C,D - - 56 65 A W III II - 13 134 
115 Muthamilselvi 215 35 F HS SS N W N C - - 45 57 A W III II - 220 478 
116 Chitra 216 27 F HS,B SS N M Y C - - 40 43 W W III II - 184 170 
117 Rani 219 22 F HS SS N M N C,A - - 60 63 W W III I - 141 333 
118 Lakshmi 220 34 F B NL N M Y A - - 36 45 A W III II oc 244 354 
119 Selvaraj 221 43 M HS NL N M Y A - - 48 54 A W III II hz 116 362 
120 Sivaraj 222 42 M HS NL N M Y A - - 48 54 A W III II - 265 413 
121 Padmavathy 226 33 F HS PS Y W Y A - - 40 45 W W III II - 191 596 
122 Jeyanthi 227 37 F UK SS N M Y C,A - - 45 52 A W III II - 154 284 
123 Chinnadurai 229 40 M HS NL Y M N A,C - - 55 55 W W III II - 296 671 
124 Muthulaxmi 230 42 F HS NL N W Y A - - 48 50 W W III II - 257 440 
125 Ravi 231 46 M HS PS Y M N A - - 50 56 A A III II oc 75 142 
126 Mankayarkarsi 232 31 F HS PS N M Y A,B - - 34 34 W W III III - 273 454 
127 Ravi 233 35 M HS SS Y SP N C,A - - 55 58 W W III II - 193 686 
128 Chinnnathal 234 55 F HS PS N M N A P I 38 43 A W III II tb 242 387 
129 Kamaudeen 237 41 F HS PS Y M N A - - 56 60 W W III III - 248 578 
130 Jeyakodi 238 42 F HS PS Y S N A - - 51 55 W W III II - 68 203 
131 Kanthan 239 35 M HS PS Y M N C - - 60 68 W W III II - 237 647 
132 Neelakandan 240 27 M HS PS Y S N A,B - - 41 49 A W III II - 210 468 
133 Rajendran 242 34 M HS SS Y M N A - - 54 58 W W IV II oc,cryM 36 18 
134 Shagrupan 243 33 F UK PS N M N B P I 40 51 A W IV II oc,tb 240 435 
135 Geetharani 246 30 F HS CL Y W Y A - - 68 75 W W III II - 194 251 
136 Latha 250 27 F HS NL N W Y A - - 40 45 A W III II - 258 478 
137 Shankar 257 25 M HS PS N S N A - - 48 55 W W III II oc 113 356 
138 Antonyravi 258 34 M HS SS N SP Y A - - 53 57 W W II I - 102 527 
139 Jeyakanthan 260 37 M HS SS N M Y C - - 54 55 W W III II - 101 346 
140 Pandiyan 264 27 M HS PS Y M Y C - - 51 55 W W III II oc 254 529 
141 Thangarasu 267 45 M HS SS Y M N A,C - - 44 44 A W III II - 251 557 
142 Nadimuthu 269 39 M HS SS Y M N B,A P I 52 50 A W III II tb 277 435 
143 Manivelu 271 32 M HS PS Y M N C,A - - 56 57 W W II II - 153 411 
144 Chitra 273 20 F HS PS N W       N B,A P I 31 40 A W III II oc,tb 127 171 
145 Meena 275 22 F HS PS N W Y C,A - - 45 45 W W III II oc 104 318 
146 Parthiban 277 36 M HS SS N S N B P I 37 49 A W III II oc,tb 100 356 
147 Muthuram 278 27 M HS PS N S N C,A - - 61 65 A W III II - 77 230 
148 Sakthivel 296 33 M HS SS Y M N A,B P I 55 45 A A III II oc,tb 345 393 
 
 
Tuberculosis Weight Functional status 
WHO 
clinical 
staging 
CD4 
count 
Sl.no Name ART No Age 
S
e
x 
Risk 
factor Education 
Employed 
Y/N 
Family 
H/o 
Family 
Members 
Affected 
Y/N 
ART 
Regi
men  Class 
 
Regi
men 
Pre 
ART 
Post 
ART 
Pre 
ART 
Post 
ART 
Pre 
ART 
Post 
ART 
OI 
Pre 
ART 
Post 
ART 
149 Kannan 298 32 F HS PS N M Y A,D - - 46 53 A W III II cmv 8 411 
150 Selvi 310 27 F HS PS Y M Y A - - 42 45 W W II II - 44 226 
151 Chinnaponnu 313 30 F HS NL Y W N A - - 37 38 W W III II - 216 493 
152 Selvaraj 320 45 M HS SS Y M Y D,C P I 61 65 W W III II tb 184 393 
153 Krishnan 323 32 M HS SS Y M N C - - 50 55 W W III II - 76 231 
154 Jeyarani 324 52 F HS NL Y W N A,B P I 37 40 A W III II tb 121 226 
155 Natarajan 332 32 M HS SS Y M N C - - 51 55 W W III II oc 102 395 
156 Kumar 335 37 M HS PS Y M Y C - - 49 54 W W III II oc 127 382 
157 Subramanian 337 33 M HS PS Y S N A - - 37 39 W W III I oc 60 224 
158 Natarajan 338 47 M HS PS Y S Y A - - 49 54 A E III II oc 122 142 
159 Gomaty 339 29 F HS SS N M Y A - - 40 44 W W III II - 300 548 
160 Indira 341 29 F HS PS Y W Y A - - 55 58 W W II I - 180 398 
161 Rajappa 342 40 M HS PS Y S N B,A EP I 50 49 W W III II oc,tb 157 460 
162 Elandran 343 38 M HS PS Y M N A - - 42 46 W W III II oc 23 301 
163 Sivakumar 345 30 M HS SS Y M Y A,B P I 41 45 W W III II oc,tb 121 340 
164 Jeyakumar 351 31 M HS SS Y M N C - - 52 57 W W II II - 168 252 
165 Tamilselvi 352 30 F HS PS Y W Y A - - 40 44 W W III II oc 350 534 
166 Veerasamy 354 45 M HS PS Y S N A - - 39 41 A A III II oc 279 492 
167 Vinoth 357 35 M HS NL Y M Y C - - 52 57 A W III II - 88 389 
168 Karupuvairam 359 32 M HS SS Y M Y A - - 40 44 W W II II oc 54 302 
169 Kannan 361 35 M HS SS Y M N A - - 36 45 A W III III oc 51 248 
170 Latha 362 27 F HS CL Y W Y A,B - - 44 46 W W II I oc 295 368 
171 Shanmugam 363 40 M HS PS Y M N B P I 53 62 A W III II oc,tb 197 552 
172 Rajeswari 371 27 F HS PS Y W Y A - - 38 43 W W III II - 156 375 
173 Senthil 375 52 M HS SS Y M N A - - 53 63 A W III II oc 131 529 
174 Manonmani 383 45 F HS SS N W Y A P I 40 53 A A III II oc,tb 31 387 
175 Selvaraj 386 36 M HS SS Y S N A - - 43 45 A A III II oc 80 261 
176 Balasubramani 391 45 M HS PS Y M Y C - - 56 61 W W III II - 65 337 
177 Chandrababu 395 40 M HS PS Y M Y B,A P I 43 51 A W III II oc,tb 98 144 
178 Kannnayan 397 37 M HS CL Y M Y A - - 62 65 W W II II oc 267 206 
179 Syadhursain 407 39 M HS PS Y M N A - - 57 59 W W II II - 195 354 
180 Suseela 285 46 F HS NL N W Y B P I 53 65 A A III III oc,tb 173 407 
181 Sekar 8 36 M HS PS Y M Y A - - 50 73 A W III I - 83 253 
182 Velayutham 50 33 M HS SS Y M N BAC EP I 52 45 A A III II oc,tb 40 143 
183 Natarajan 344    44 M UK PS Y M N A - -     40   45 A W III I oc,pcp 55 181 
 
 
 
LIST OF ABBREVIATIONS 
 
 
HS - Heterosexual 
B   - Blood transfusion 
UK - Unknown 
IDU - I.V.Drug user 
PS - Primary school 
SS - Secondary school 
CL - College or above 
NL - Non - literate 
M - Married 
W - Widow 
S - Single 
SP - Separated 
P - Pulmonary 
EP - Extra pulmonary 
Oc - Oral candidiasis 
TB - Tuberculosis 
TBM - Tuberculous meningitis 
TBL - Tuberculous lymphadenopathy 
PCP - Pneumocystis carinii pneumonia 
CMV - Cytomegalovirus infection 
HZ - Herpes zoster 
CryM - Cryptococcal meningitis 
ART Regimens - see page number: 37 
Functional status class - see page number: 36 
WHO clinical staging - see page number: 33 
 
 
 
